These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21737454)

  • 21. BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.
    Ouarné M; Bouvard C; Boneva G; Mallet C; Ribeiro J; Desroches-Castan A; Soleilhac E; Tillet E; Peyruchaud O; Bailly S
    J Exp Clin Cancer Res; 2018 Aug; 37(1):209. PubMed ID: 30165893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis.
    Owen NE; Alexander GJ; Sen S; Bunclark K; Polwarth G; Pepke-Zaba J; Davenport AP; Morrell NW; Upton PD
    EBioMedicine; 2020 Jun; 56():102794. PubMed ID: 32454407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
    Jonker L
    Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis.
    Hawinkels LJ; Kuiper P; Wiercinska E; Verspaget HW; Liu Z; Pardali E; Sier CF; ten Dijke P
    Cancer Res; 2010 May; 70(10):4141-50. PubMed ID: 20424116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
    David L; Mallet C; Keramidas M; Lamandé N; Gasc JM; Dupuis-Girod S; Plauchu H; Feige JJ; Bailly S
    Circ Res; 2008 Apr; 102(8):914-22. PubMed ID: 18309101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.
    Ardelean DS; Jerkic M; Yin M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M
    Angiogenesis; 2014 Jan; 17(1):129-46. PubMed ID: 24061911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BMP9 regulates endoglin-dependent chemokine responses in endothelial cells.
    Young K; Conley B; Romero D; Tweedie E; O'Neill C; Pinz I; Brogan L; Lindner V; Liaw L; Vary CP
    Blood; 2012 Nov; 120(20):4263-73. PubMed ID: 23018639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoglin in angiogenesis and vascular diseases.
    ten Dijke P; Goumans MJ; Pardali E
    Angiogenesis; 2008; 11(1):79-89. PubMed ID: 18283546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BMP9 Crosstalk with the Hippo Pathway Regulates Endothelial Cell Matricellular and Chemokine Responses.
    Young K; Tweedie E; Conley B; Ames J; FitzSimons M; Brooks P; Liaw L; Vary CP
    PLoS One; 2015; 10(4):e0122892. PubMed ID: 25909848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
    Tillet E; Bailly S
    Front Genet; 2014; 5():456. PubMed ID: 25620979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoglin for tumor imaging and targeted cancer therapy.
    Paauwe M; ten Dijke P; Hawinkels LJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BMP9 and BMP10: Two close vascular quiescence partners that stand out.
    Desroches-Castan A; Tillet E; Bouvard C; Bailly S
    Dev Dyn; 2022 Jan; 251(1):178-197. PubMed ID: 34240497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum/glucocorticoid-regulated kinase 1 as a novel transcriptional target of bone morphogenetic protein-ALK1 receptor signaling in vascular endothelial cells.
    Araki M; Hisamitsu T; Kinugasa-Katayama Y; Tanaka T; Harada Y; Nakao S; Hanada S; Ishii S; Fujita M; Kawamura T; Saito Y; Nishiyama K; Watanabe Y; Nakagawa O
    Angiogenesis; 2018 May; 21(2):415-423. PubMed ID: 29478089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
    Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
    Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development.
    Chen H; Brady Ridgway J; Sai T; Lai J; Warming S; Chen H; Roose-Girma M; Zhang G; Shou W; Yan M
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11887-92. PubMed ID: 23812757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia.
    Gallardo-Vara E; Tual-Chalot S; Botella LM; Arthur HM; Bernabeu C
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30108051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoglin regulates mural cell adhesion in the circulatory system.
    Rossi E; Smadja DM; Boscolo E; Langa C; Arevalo MA; Pericacho M; Gamella-Pozuelo L; Kauskot A; Botella LM; Gaussem P; Bischoff J; Lopez-Novoa JM; Bernabeu C
    Cell Mol Life Sci; 2016 Apr; 73(8):1715-39. PubMed ID: 26646071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
    Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.
    Breen MJ; Moran DM; Liu W; Huang X; Vary CP; Bergan RC
    PLoS One; 2013; 8(8):e72407. PubMed ID: 23967299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.
    Eleftheriou NM; Sjölund J; Bocci M; Cortez E; Lee SJ; Cunha SI; Pietras K
    Oncotarget; 2016 Dec; 7(51):84314-84325. PubMed ID: 27741515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.